Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany

维多利祖马布 医学 Golimumab公司 英夫利昔单抗 阿达木单抗 溃疡性结肠炎 内科学 炎症性肠病 中止 胃肠病学 肿瘤坏死因子α 疾病
作者
Ulf Helwig,Karel Kostev,Carsten Schmidt
出处
期刊:Journal of Clinical Gastroenterology [Lippincott Williams & Wilkins]
卷期号:55 (1): e1-e7 被引量:5
标识
DOI:10.1097/mcg.0000000000001323
摘要

The goal of the study was to compare persistence with vedolizumab versus adalimumab, golimumab, and infliximab in biologics-naïve patients with inflammatory bowel disease treated in gastroenterological practices and outpatient clinics in Germany.Patients aged 18 or older who had initiated a biological therapy (vedolizumab, infliximab, adalimumab, or golimumab) were included in the present study. Prescriptions between July 2014 and March 2017 of the respective biological drug emerging from gastroenterological practices or outpatient clinics in Germany were retrieved from the longitudinal prescription (LRx) database. Patients treated with vedolizumab were matched with patients treated with infliximab, adalimumab, or golimumab on the basis of age, gender, medication before biologic therapy, and index year. The primary outcome variable of the study was the rate of persistence with vedolizumab compared with antitumor necrosis factor biologics (infliximab, adalimumab, and golimumab) within 3 years of the first prescription in outpatient settings.Kaplan-Meier analysis was performed in 15,984 patients naïve to biologics revealing the statistically lower risk of discontinuation for vedolizumab compared with adalimumab, golimumab, or infliximab. In matched-pairs analyses, within 3 years after the first prescription, 39.5% of 2076 patients were persistent to vedolizumab compared with 33.5% of matched patients persistent to adalimumab (P<0.001). 37.6% of 716 patients were persistent to vedolizumab compared with 24.7% of matched patients persistent to golimumab (P<0.001). 35.7% of 2055 patients were persistent to vedolizumab compared with 30.2% of matched patients persistent to infliximab (P=0.119). Vedolizumab was associated with a significantly lower risk of therapy discontinuation compared with adalimumab [hazard ratio (HR)=0.86; 95% confidence interval (CI), 0.81-0.93] and golimumab (HR=0.60; 95% CI, 0.54-0.67), respectively; the vedolizumab risk of therapy discontinuation was numerically lower than infliximab but statistical significance was not achieved (HR=0.93; 95% CI, 0.85-1.02).In biologics-naïve IBD patients treated in outpatient settings in Germany, matched-pair analyses showed that vedolizumab was associated with significantly improved drug persistence compared with adalimumab or golimumab, whereas numerical improvement was shown in comparison with infliximab.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
超级的听南完成签到,获得积分10
1秒前
深情安青的应助被AKYDXS采纳,获得10
1秒前
M2106完成签到,获得积分10
1秒前
难过兔子发布了新的文献求助10
2秒前
2秒前
科研通AI6.2的应助被yqy采纳,获得10
2秒前
2秒前
2秒前
漫漫发布了新的文献求助10
3秒前
Orange的应助被Azur1采纳,获得10
3秒前
conshy发布了新的文献求助10
3秒前
默默毛豆完成签到 ,获得积分10
5秒前
7秒前
zjy发布了新的文献求助10
7秒前
成就念芹完成签到,获得积分10
7秒前
Nutter发布了新的文献求助10
7秒前
lx的应助被skylee9527采纳,获得10
7秒前
沐风发布了新的文献求助10
7秒前
小薇薇完成签到,获得积分10
7秒前
8秒前
8秒前
彭于晏的应助被Lx采纳,获得10
8秒前
FashionBoy的应助被忧郁的采萱采纳,获得10
9秒前
9秒前
10秒前
11秒前
称心的猪完成签到,获得积分10
11秒前
12秒前
12秒前
wkkk发布了新的文献求助10
13秒前
xiaoxie发布了新的文献求助10
13秒前
yjy完成签到,获得积分10
13秒前
科科发布了新的文献求助10
14秒前
咕咕鸡完成签到,获得积分10
14秒前
华仔的应助被hgyu采纳,获得10
15秒前
AKYDXS发布了新的文献求助10
17秒前
17秒前
宁宁发布了新的文献求助10
17秒前
18秒前
偶然的风41177完成签到,获得积分0
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168483
求助须知:如何正确求助?哪些是违规求助? 9561528
关于积分的说明 21761791
捐赠科研通 7760121
什么是DOI,文献DOI怎么找? 3430046
关于科研通互助平台的介绍 2553908
邀请新用户注册赠送积分活动 2474667